About Us - id.normaxbiomed.com

About UsPeter A. Jensen2023-05-16T08:28:48+00:00

Normax Biomed Limited (Normax) is an mRNA Vaccine research and development and manufacturing company located in Ireland and the United Kingdom.

Normax is dedicated to deliver mRNA Vaccines for infectious diseases to help support the Sustainable Development Goal (SDG) for GOOD HEALTH AND WELL-BEING (Goal 3) to ensure healthy lives and promote well-being for all at all ages, in synergy with the 17 Goals of The 2030 Agenda for Sustainable Development of the United Nations (UN).

Normax is committed to deliver competitive financial performance for investors.

Why mRNA Vaccines

In principle, mRNA vaccine technology can be developed to prevent or treat any disease. mRNA Vaccines have been proven safe and effective to save lives and help end the pandemic.

Our aim is to develop and manufacture mRNA Vaccines for a wide array of diseases with our partners from the mRNA UCV Consortium and Vax Factory. This collaborative process will enable Normax to market mRNA vaccines for large scale advance purchase agreements (APA) at an affordable price of about $4 dollars per dose.

Our Purpose. Our Process. Our Result.

WHY. Our Purpose.

Deliver mRNA Vaccines to save lives.

Help Enable Pandemic Preparedness
Support Global Public Health
Help Prevent and Cure Disease
Save Lives and Prevent Human Misery
Help to prevent future Pandemics

HOW. Sustained Process.

Safe and effective mRNA Vaccines.

People, Partners and Knowledge
Leading Science and Technology
Private and Public Impact Investment
Advance Purchase Agreements (APA)
Vaccine Manufacturing in modular GMP Vax Factories

WHAT. Collective Results.

Affordable mRNA Vaccines for all.

mRNA Vaccines for Disease and Cancers
Vaccine Manufacturing and Fill-Finish
mRNA Vaccine Platform
mRNA Vaccines for Public Health
Support Pandemic Preparedness for all

Our Team

We have recruited a skilled, balanced and diverse key executive team with average 25 years experience per key executive

Peter A. Jensen MFA BSc

CEO & Chairman, Normax Biomed Limited

Biologist. Leader. Collaborator. Inventor. Entrepreneur. Producer. Innovator. CEO.

Mr. Jensen is a high-performance CEO and business manager with extensive expertise in life sciences, computer sciences, mobile, multimedia, entertainment, fintech, finance and distributed ledger technology. Mr. Jensen earned a Master of Fine Arts (MFA) at UCLA Motion Picture Film and Television Producer’s Program (1988) and a Bachelor of Arts (BA) in Biological Sciences at UCSB (1980) magna cum laude. Mr. Jensen is an experienced key executive business manager and entrepreneur with a superlative track record.

Mr. Jensen invented and delivered: (i) the world’s first mobile app for Ericsson (1999) on the first prototype smartphone, (ii) the world’s first real-time tissue realistic 3D surgical training system for robotic laparoscopic surgery, with SINTEF and The Intervention Centre centre for image guided and minimally invasive therapy at Oslo University Hospital and (iii) a 50x for early-stage investors in The Mobile Media Company (2000). Mr. Jensen is focused on development of investment products for competitive ROI and extraordinary social impact.

Innovative achievements over 36 years

Chief Financial Officer (CFO) & Controller. FCA. (40 years)

Chief Medical Officer (CMO) & Clinical Bioinformatics. MD FACMI FACP (35 years)

Chief Medical Officer (CMO) & Clinical Vaccine Safety. MD PhD MPP (40 years)

Chief Financial Officer (CFO) USA. MBA. (35 years)

Chief Strategy Officer (CSO). BSc. MEng. (35 years)

Chief Technology Officer (CTO) Siv.ing. MSc. (20 years)

Chief Software Engineer. PhD (25 years)

Vice President Finance. CPA (35 years)

Vice President Projects. M.Arch (10 years)

Vice President Projects. MSc. (15 years)

Vice President Projects. MBA (15 years)

Vice President Administration. RN (10 years)

Normax has engaged Deloitte (Ireland) for Tax, Governance, Risk, Sustainability and Technical Accounting Advisory Services and Deloitte (UK) for Location Advisory Services and Human Resource (HR) Advisory. Normax has engaged Grant Thornton (Ireland) for Audit Services. Normax has engaged Mason Hayes & Curran (Ireland) and CMS (Switzerland) and Cooley (UK) as legal advisors.

Our Board of Directors

Peter A. Jensen, MFA BSc

Director

Martin W. Stevens, FCA

Director

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.Peter A. Jensen2023-02-03T11:00:00+00:00

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.

This website includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “will,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements about our beliefs and expectations and the estimated financial information and other projections contained herein. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Normax Biomed Ltd. are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements. Please refer to the final prospectus of Normax Biomed Limited under “Risk Factors” therein, and other documents filed or to be filed with the London Stock Exchange and the Swiss Stock Exchange (SIX) by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Normax Biomed Ltd. undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the listing requirements of the London Stock Exchange and the Swiss Stock Exchange (SIX).

This website is directed only at, and provides information about products and services only available to, those who are Professional Clients or Eligible Counterparties as defined by the Financial Conduct Authority. The definitions can be found on the FCA website at www.fca.org.uk. This website is not intended to be accessed by any persons or entities domiciled in any jurisdiction where being treated as the types of clients stated would be contrary to local law.

Normax AbstractPeter A. Jensen2022-08-31T11:50:39+00:00

Normax Abstract

Normax Biomed Ltd (Normax) is based in Cork, Ireland, and London, England. Normax is in the business of mRNA vaccine Research, Development and Manufacturing. Normax has secured a €300,000,000 capital commitment from a $3.4Bn cornerstone institutional investor for development of mRNA Vaccines and Vax Factory Manufacturing for Transformative Social Impact on Infectious Disease and Pandemic Preparedness. Normax plans to drive down the cost of mRNA Vaccines to save more lives and to deliver sustainable returns for impact investors. Normax plans to deliver safe and effective mRNA vaccines at large scale for about $4 dollars per dose. Normax mRNA vaccine products in development include: (1) mRNA Vax Factory, (2) Universal Coronavirus mRNA Vaccine, (3) Tuberculosis mRNA Vaccine, (4) HIV mRNA Vaccine, (5) Malaria mRNA Vaccine, and (6) Disease-X mRNA Vaccine (e.g. within 100 days). Normax mission is to deliver competitive financial performance with transformative social impact. NOT AN OFFER TO INVEST.